Literature DB >> 10651946

Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.

T Iwasaki1, T Hamano, K Saheki, T Kuroiwa, Y Kataoka, Y Takemoto, A Ogata, J Fujimoto, E Kakishita.   

Abstract

The graft-versus-host disease (GVHD) generated in BDF1 mice by the injection of spleen cells from the C57BL/6 parental strain induces a direct cell-mediated attack on host lymphohaematopoietic populations, resulting in the reconstitution of the host with donor cells. We examined Fas-Fas ligand (FasL) interactions in donor and host haematopoietic cells over a prolonged period of parental-induced GVHD. Fas expression on bone marrow cells of both donor and host origin increased at 2 weeks. Host cell incubation with anti-Fas antibody induced apoptosis, and the number of haematopoietic progenitor cells decreased. Fas-induced apoptosis by the repopulating donor cells, however, did not increase until 12 weeks, when more than 90% of the cells were donor cells. The expression of various cytokines, such as interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), and FasL gene expression in the bone marrow increased concomitantly. To examine directly whether FasL has a major role in the development of donor cell engraftment, FasL-deficient (gld) mice were used as donors. Injection of B6/gld spleen cells induced significantly less host lymphohaematopoietic depletion, resulting in a failure of donor cell engraftment. Furthermore, injection of IFN-gamma gene knockout (gko) B6 spleen cells failed to augment Fas and FasL expression in recipient mice, resulting in a failure of donor cell engraftment. This suggests that the induction of apoptosis by Fas-FasL interactions in host cells may contribute to a reconstitution of the host with donor cells and that donor-derived IFN-gamma plays a significant role for Fas-FasL interactions in host cells during parental-induced GVHD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651946      PMCID: PMC2327118          DOI: 10.1046/j.1365-2567.2000.00919.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

1.  Abrogation of hybrid resistance to bone marrow engraftment by graft-vs-host-induced immune deficiency.

Authors:  F T Hakim; G M Shearer
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

2.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.

Authors:  B Lowin; M Hahne; C Mattmann; J Tschopp
Journal:  Nature       Date:  1994-08-25       Impact factor: 49.962

3.  Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts.

Authors:  R Kiessling; P S Hochman; O Haller; G M Shearer; H Wigzell; G Cudkowicz
Journal:  Eur J Immunol       Date:  1977-09       Impact factor: 5.532

Review 4.  Biology and genetics of hybrid resistance.

Authors:  M Bennett
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

Review 5.  Mechanisms of early allogeneic marrow graft rejection.

Authors:  H von Melchner; P F Bartlett
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

6.  Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction.

Authors:  A M Mowat
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

7.  Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice injected with parental lymphocytes.

Authors:  F T Hakim; S O Sharrow; S Payne; G M Shearer
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

8.  Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.

Authors:  C S Via; S O Sharrow; G M Shearer
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

9.  Loss of proliferative capacity and T cell immune development potential by bone marrow from mice undergoing a graft-vs-host reaction.

Authors:  T Iwasaki; H Fujiwara; T Iwasaki; G M Shearer
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

10.  Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.

Authors:  P F Piguet; G E Grau; B Allet; P Vassalli
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  4 in total

1.  The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease.

Authors:  Y Kataoka; T Iwasaki; T Kuroiwa; Y Seto; N Iwata; N Hashimoto; A Ogata; T Hamano; E Kakishita
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 2.  Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction.

Authors:  H J Deeg
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

3.  Attenuation of GVHD for allo-bone marrow transplantation recipient by FasL-Fas pathway in an H-2 haplotype disparate mouse combination.

Authors:  Lingbo Liu; Ping Zou; Zhongbo Hu; Zhaodong Zhong; Juan Xiao; Rong Guo; Zhiliang Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

Review 4.  The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.

Authors:  Hui Wang; Yong-Guang Yang
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.